Serotonin 2A receptor antagonists for treatment of schizophrenia (Q37899193)

25 August 2017

1 reference

title

Serotonin 2A receptor antagonists for treatment of schizophrenia (English)

1 reference

5-hydroxytryptamine receptor 2A

25 August 2017

0 references

0 references

0 references

4

Birte Glenthøj

0 references

author name string

Bjørn H Ebdrup

series ordinal

1

1 reference

25 August 2017

Hans Rasmussen

series ordinal

2

1 reference

25 August 2017

Jørn Arnt

series ordinal

3

1 reference

25 August 2017

language of work or name

English

0 references

publication date

8 July 2011

1 reference

Expert Opinion on Investigational Drugs

25 August 2017

1 reference

25 August 2017

20

1 reference

25 August 2017

9

1 reference

25 August 2017

1211-1223

1 reference

Schizophrenia: a concise overview of incidence, prevalence, and mortality

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

The Economic Burden of Schizophrenia in the United States in 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Antipsychotic drug doses and neuroleptic/dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Serotonin receptors: their key role in drugs to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Drugs which antagonize 5-hydroxytryptamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Serotonin research: contributions to understanding psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Neurotransmitter Receptors in Frontal Cortex of Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Decreased frontal cortical serotonin2A receptors in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Decreased serotonin2A receptors in Brodmann's area 9 from schizophrenic subjects. A pathological or pharmacological phenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Alterations in the cortical serotonergic system in schizophrenia: a postmortem study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

5-HT2A and muscarinic receptors in schizophrenia: a postmortem study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Serotonin2 receptors and the serotonin transporter in the schizophrenic brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Identification of a serotonin/glutamate receptor complex implicated in psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Decreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Cortical and Subcortical 5-HT2A Receptor Binding in Neuroleptic-Naive First-Episode Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Heritability estimates for psychotic disorders: the Maudsley twin psychosis series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

The 5-HT2A receptor binding pattern in the human brain is strongly genetically determined

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Negative association between T102C polymorphism of the 5-HT2a receptor gene and schizophrenia in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Sensorimotor gating of schizophrenia patients is influenced by 5-HT2A receptor polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Role of serotonin 2A receptors in the D-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Serotonin 5-HT(2) receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Pathophysiologically based treatment interventions in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Enhanced function of prefrontal serotonin 5-HT(2) receptors in a rat model of psychiatric vulnerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100,907 PET and non-invasive kinetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

Serotonin-dopamine interaction and its relevance to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601738

10.1517/13543784.2011.601738

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference